Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncolytic adenovirus treatment of a patient with refractory neuroblastoma.

Literature DB >> 19735000

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma.

Sari Pesonen¹, Heikki Helin, Petri Nokisalmi, Sophie Escutenaire, Camilla Ribacka, Merja Sarkioja, Vincenzo Cerullo, Kilian Guse, Gerd Bauerschmitz, Leena Laasonen, Teemu Kantola, Ari Ristimaki, Maria Rajecki, Minna Oksanen, Elina Haavisto, Anna Kanerva, Timo Joensuu, Akseli Hemminki.

Abstract

Entities: Disease Species

Mesh：

Year: 2010 PMID： 19735000 DOI： 10.3109/02841860903071369

Source DB: PubMed Journal: Acta Oncol ISSN： 0284-186X Impact factor: 4.089

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

Authors: Vincenzo Cerullo; Iulia Diaconu; Lotta Kangasniemi; Maria Rajecki; Sophie Escutenaire; Anniina Koski; Valentina Romano; Noora Rouvinen; Tamara Tuuminen; Leena Laasonen; Kaarina Partanen; Satu Kauppinen; Timo Joensuu; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Anna Kanerva; Sari Pesonen; Petteri T Arstila; Akseli Hemminki
Journal: Mol Ther Date: 2011-06-14 Impact factor: 11.454

2. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors: Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal: Mol Ther Date: 2012-07-24 Impact factor: 11.454

Review 3. Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors: M D Kumar; A Dravid; A Kumar; D Sen
Journal: Cancer Gene Ther Date: 2016-04-15 Impact factor: 5.987

4. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Authors: Chuan Jin; Di Yu; Matko Čančer; Berith Nilsson; Justyna Leja; Magnus Essand
Journal: Hum Gene Ther Date: 2013-08 Impact factor: 5.695

5. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

Authors: Anna Kanerva; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Timo Joensuu; Otto Hemminki; Juni Palmgren; Kari Hemminki; Akseli Hemminki
Journal: Mol Ther Date: 2014-11-10 Impact factor: 11.454

6. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

Authors: Yuan Li; Baofu Zhang; Hongwei Zhang; Xiaoyu Zhu; Dongchuan Feng; Deyong Zhang; Baobiao Zhuo; Liantao Li; Junnian Zheng
Journal: J Cancer Res Clin Oncol Date: 2013-02-27 Impact factor: 4.553

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma.

1. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

2. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Review 3. Gene therapy as a potential tool for treating neuroblastoma-a focused review.

4. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

5. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

6. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

Review 7. Oncolytic virotherapy: the questions and the promise.

Review 8. Targeting pediatric cancer stem cells with oncolytic virotherapy.

9. Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.

10. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.